[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medtronic Vascular\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":186},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,77,102,122,142,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601857","streamlined-denervation-with-spyral-for-an-optimized-treatment-spyral-swyft-in-subjects-with-uncontrolled-hypertension-100601857",false,"NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%","ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[27,28,29,30,31],"Hypertension","Vascular Diseases","Cardiovascular Diseases","Chronic Kidney Diseases","Diabetes Mellitus","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2025-09-22",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Medtronic Vascular","INDUSTRY",21,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100585805","spyral-gemini-pilot-study-100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.","80 Years",{"count":55,"type":21},175,[24],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[27,28,29,30,31],[60,61,62,63,64,27,29,28,65,66,67],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Kidney Diseases","Denervation","Renal Denervation","Hepatic Denervation","2026-06-22",{"date":70,"type":36},"2026-06-24",{"date":72,"type":36},"2025-05-01",{"date":74,"type":21},"2029-12-22",{"name":42,"class":43},18,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100594014","spyral-insight-study-100594014","NCT07013929","Spyral InSight Study","Spyral InSight Early Clinical Feasibility Study","Spyral InSight","Inclusion Criteria:\n\n1. 20 - 70 years of age\n2. Office SBP ≥150 mmHg and \\\u003C180 mmHg and DBP ≥90 mmHg\n3. Individual is prescribed with one, two, or three antihypertensive medication classes\n4. 24-hour ABPM average of SBP ≥135 and \\\u003C170 mmHg at Baseline\n\nExclusion Criteria:\n\n1. Prior renal denervation.\n2. Individual lacks appropriate renal artery Anatomy\n3. Has a renal artery stent\n4. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C60 mL\u002Fmin\u002F1.73m2\n5. Individual is taking SGLT2 inhibitors or GLP-1 agonists\n6. Individual requires chronic oxygen support or mechanical ventilation\n7. Primary pulmonary hypertension.\n8. Secondary cause of hypertension\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n11. Individual is currently taking anti-mineralocorticoid drugs.","20 Years","70 Years",{"count":88,"type":21},19,[24],"The purpose of the Spyral InSight Early Clinical Feasibility Study is to characterize the physiological response to renal nerve stimulation (RNS) in humans prior to and post renal denervation.",[27,28,29],[27,29,28,65,66],"2026-04-30",{"date":95,"type":36},"2026-05-04",{"date":97,"type":36},"2025-06-09",{"date":99,"type":21},"2027-07-01",{"name":42,"class":43},2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":101},"100173644","global-symplicity-registry-gsr-define-100173644","NCT01534299","Global SYMPLICITY Registry (GSR) DEFINE","Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)","Inclusion Criteria:\n\n* Age ≥ 18 years or minimum age as required by local regulations\n* The patient is an acceptable candidate for renal denervation based upon the Instructions For Use for the Medtronic renal denervation system. The procedure must be performed with an initial use, market-released Medtronic renal denervation catheter.\n* The patient or legal representative has been informed of the nature of the registry has consented to participate and authorized the collection and release of this medical information by signing a consent form (\"Patient Informed Consent Form\" or \"Patient Data Release Authorization Form\")",{"count":110,"type":21},5000,"OBSERVATIONAL","This is a prospective, multi-center, single-arm, non-interventional and open-label registry. The purpose of the registry is to document the long-term safety and effectiveness of renal denervation in a real world patient population with hypertension GSR DEFINE is the continuation of the Global SYMPLICITY Registry and collectively will enroll approximately 5000 patients with hypertension who undergo the renal denervation procedure, from over 300 sites worldwide. Subjects included in GSR DEFINE will be followed for a minimum of 1 year and up to 5 years post-procedure. Patients with uncontrolled hypertension will be enrolled in accordance with the inclusion criteria specified in the protocol.",[27],"2026-04-22",{"date":116,"type":36},"2026-04-27",{"date":118,"type":36},"2012-02",{"date":120,"type":21},"2031-12",{"name":42,"class":43},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100606366","longitudinal-real-world-clinical-outcomes-study-on-symplicity-renal-denervation-100606366","NCT07174622","Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation","Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data","SPYRAL CARE","Inclusion Criteria:\n\n* Enrolled in a Medicare plan\n* Diagnosis of uncontrolled hypertension\n* On a stable regimen of antihypertensive therapy\n\nExclusion Criteria:\n\n* A prior RDN procedure\n* Diagnosis of secondary hypertension\n* Any condition for which RDN is contraindicated",{"count":131,"type":21},1000,"This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.",[27,29,28],"2026-04-21",{"date":114,"type":36},{"date":137,"type":36},"2025-10-28",{"date":139,"type":21},"2029-06",{"name":42,"class":43},1,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100557264","prevail-global-study-100557264","NCT06535854","Prevail Global Study","A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).","Inclusion Criteria:\n\n* ≥ 18 years\n* Negative pregnancy test\n* Stable or unstable angina, positive functional test, or stable NSTEMI\n* Life expectancy \\>1 year\n* Willing and able to cooperate with study procedures and required follow up evaluations\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to antiplatelet medications or a sensitivity to contrast media which cannot be adequately pre-medicated\n* History of an allergic reaction or significant sensitivity to paclitaxel or any other analogue or derivative\n* Platelet count \\\u003C 100,000 cells\u002Fmm³ or \\> 700,000 cells\u002Fmm³, or a white blood cell (WBC) count \\\u003C 3,000 cells\u002Fmm³\n* Renal insufficiency (or failure)\n* Acute MI\n* Previous PCI of the target vessel within 6 months prior to the procedure\n* Planned PCI of any vessel within 30 days post-index procedure and\u002For planned PCI of the target vessel within 12 months post-procedure\n* History of a stroke or transient ischemic attack (TIA)\n* Active peptic ulcer or upper gastrointestinal (GI) bleeding\n* History of bleeding diathesis or coagulopathy or will refuse blood transfusions\n* Documented left ventricular ejection fraction (LVEF) \\\u003C30%\n* Planned surgery that would cause interruption in recommended DAPT duration per current guidelines\n* Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS or other coronary artery imaging procedures",{"count":150,"type":21},1205,[24],"The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.",[154],"Coronary Artery Disease",[156,157],"ISR","DNSV",{"date":159,"type":36},"2026-04-24",{"date":161,"type":36},"2025-02-24",{"date":163,"type":21},"2031-02",{"name":42,"class":43},51,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":141},"100599188","symplicity-china-study-100599188","NCT07081243","Symplicity China Study","A Prospective, Single-group, Non-interventional, Non-blinded, Observational Study to Evaluate the Long-term Safety, Efficacy, and Durability of Symplicity Spyral Renal Denervation System in China","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Patients diagnosed with resistant hypertension or antihypertensive drug intolerance and treated with Symplicity Spyral Renal Denervation System. Resistant hypertension, defined as having an office systolic blood pressure (SBP) ≥140 mmHg despite appropriate lifestyle measures and being treated with three or more antihypertensive medications (including a diuretic) for more than 3 months; or drug intolerance, defined as patients who cannot tolerate medication due to contraindications or adverse effects.\n3. The patient voluntarily undergoes renal denervation; the patient has been informed of the observational nature of the study; the patient voluntarily provides written informed consent (\"Patient Informed Consent Form\") and willingly participates in the study.\n\nExclusion Criteria:\n\n1. At least one main renal artery with a diameter less than 3 mm or greater than 8 mm.\n2. Presence of fibromuscular dysplasia.\n3. Renal artery stent placement within 3 months prior to the procedure.\n4. Presence of Renal artery aneurysms.\n5. Presence of more than 50% stenosis in any treatable vessel.\n6. Pregnant.\n7. Present of renal or adrenal tumors.\n8. Iliac\u002Ffemoral artery stenosis prevents catheter insertion.",{"count":174,"type":21},500,"The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of follow up.",[177],"Resistant Hypertension","2025-11-13",{"date":180,"type":36},"2025-11-17",{"date":182,"type":36},"2025-11-11",{"date":184,"type":21},"2031-12-30",{"name":42,"class":43},""]